

SPINK1 Antibody (monoclonal) (M01)

Mouse monoclonal antibody raised against a partial recombinant SPINK1.

Catalog # AT4023a

Product Information

Application	WB, IHC, IP, E
Primary Accession	P00995
Other Accession	BC025790
Reactivity	Human
Host	Mouse
Clonality	monoclonal
Isotype	IgG2a Kappa
Clone Names	4D4
Calculated MW	8507

Additional Information

Gene ID	6690
Other Names	Pancreatic secretory trypsin inhibitor, Serine protease inhibitor Kazal-type 1, Tumor-associated trypsin inhibitor, TATI, SPINK1, PSTI
Target/Specificity	SPINK1 (AAH25790, 24 a.a. ~ 79 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Dilution	WB~~1:500~1000 IHC~~1:100~500 IP~~N/A E~~N/A
Format	Clear, colorless solution in phosphate buffered saline, pH 7.2 .
Storage	Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
Precautions	SPINK1 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.

Background


The protein encoded by this gene is a trypsin inhibitor, which is secreted from pancreatic acinar cells into pancreatic juice. It is thought to function in the prevention of trypsin-catalyzed premature activation of zymogens within the pancreas and the pancreatic duct. Mutations in this gene are associated with hereditary pancreatitis and tropical calcific pancreatitis.

References


1.HOXB13 G84E-related Familial Prostate Cancers: A Clinical, Histologic, and Molecular Survey.Smith SC, Palanisamy N, Zuhlke KA, Johnson AM, Siddiqui J, Chinnaiyan AM, Kunju LP, Cooney KA, Tomlins SA
Am J Surg

Pathol. 2014 May;38(5):615-26. doi: 10.1097/PAS.0000000000000090.2. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. Bhalla R, Kunju LP, Tomlins SA, Christopherson K, Cortez C, Carskadon S, Siddiqui J, Park K, Miguel Mosquera J, Pestano GA, Rubin MA, Chinnaiyan AM, Palanisamy N. Mod Pathol. 2013 Jan 25. doi: 10.1038/modpathol.2012.234.3. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. Rink M, Park K, Volkmer BG, Xylinas E, Hansen J, Cha EK, Robinson BD, Hautmann R, Kufer R, Engel O, Chun FK, Dahlem R, Rubin MA, Shariat SF, Mosquera JM. Urol Oncol. 2012 Sep 1. pii: S1078-1439(12)00237-2. doi: 10.1016/j.urolonc.2012.06.011.4.325 DIFFERENCES IN TMPRSS2-ERG GENE FUSION AND SPINK1 OVEREXPRESSION IN PROSTATE CANCER IN AFRICAN-AMERICAN AND CAUCASIAN MEN. Khani F, Mosquera JM, Park K, Srivastava A, Tewari A, Rubin M, Robinson B. The Journal of Urology Volume 187, Issue 4, Supplement, April 2012, Pages e1325. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, Linetzky KA, Palanisamy N, Zhou M, Chinnaiyan AM, Shah RB. Mod Pathol. 2009 Sep;22(9):1176-85. Epub 2009 May 22.6. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andren O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A. Cancer Cell. 2008 Jun;13(6):519-28.


Images




Antibody Reactive Against Recombinant Protein. Western Blot detection against Immunogen (31.9 kDa) .




SPINK1 monoclonal antibody (M01), clone 4D4. Western Blot analysis of SPINK1 expression in human pancreas.



Immunoperoxidase of monoclonal antibody to SPINK1 on formalin-fixed paraffin-embedded human pancreas. [antibody concentration 1 ug/ml]



Immunoprecipitation of SPINK1 transfected lysate using anti-SPINK1 monoclonal antibody and Protein A Magnetic Bead ([U0007](#)), and immunoblotted with SPINK1 MaxPab rabbit polyclonal antibody.



Detection limit for recombinant GST tagged SPINK1 is 0.03 ng/ml as a capture antibody.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.